What is the Olaparib?

Olaparib is , while it's Molecular Formula is C 24 H 23 FN 4 O 3 . Many of the products generated by alkylating agents on DNA can be efficiently repaired by normal base excision repair (BER). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in BER. Olaparib is a potent inhibitor of PARP1 and PARP2 (IC50 = 5 and 1 nM, respectively) but is less effective against the PARP tankyrase-1 (IC50 = 1.5 μM). It can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.[Cayman Chemical]

What is the CAS number for Olaparib?

The CAS number of Olaparib is 763113-22-0.

What is Olaparib (763113-22-0) used for?

Many of the products generated by alkylating agents on DNA can be efficiently repaired by normal base excision repair (BER). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in BER. Olaparib is a potent inhibitor of PARP1 and PARP2 (IC50 = 5 and 1 nM, respectively) but is less effective against the PARP tankyrase-1 (IC50 = 1.5 μM). It can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.InChI:InChI=1/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)

What is the Olaparib?

Olaparib is , while it's Molecular Formula is C 24 H 23 FN 4 O 3 . Many of the products generated by alkylating agents on DNA can be efficiently repaired by normal base excision repair (BER). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in BER. Olaparib is a potent inhibitor of PARP1 and PARP2 (IC50 = 5 and 1 nM, respectively) but is less effective against the PARP tankyrase-1 (IC50 = 1.5 μM). It can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.[Cayman Chemical]

What is the CAS number for Olaparib?

The CAS number of Olaparib is 763113-22-0.

What is Olaparib (763113-22-0) used for?

Many of the products generated by alkylating agents on DNA can be efficiently repaired by normal base excision repair (BER). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in BER. Olaparib is a potent inhibitor of PARP1 and PARP2 (IC50 = 5 and 1 nM, respectively) but is less effective against the PARP tankyrase-1 (IC50 = 1.5 μM). It can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.InChI:InChI=1/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)

Product Class

763113-22-0

Product Name：Olaparib
Molecular Formula：C₂₄H₂₃FN₄O₃
Purity：99%
Molecular Weight：434.47

Inquiry

Product Details:

CasNo： 763113-22-0

Molecular Formula： C₂₄H₂₃FN₄O₃

Factory Sells 763113-22-0 Safe Shipping, Buy High Grade Olaparib

Molecular Formula:C₂₄H₂₃FN₄O₃
Molecular Weight:434.47
Refractive Index:1.702
PKA:12.07±0.40(Predicted)
PSA：86.37000
Density:1.43 g/cm³
LogP:2.22320

Olaparib(Cas 763113-22-0) Usage

Description	Olaparib, marketed as Lynparza, is an oral medication developed by AstraZeneca. It falls under the class of poly(ADP-ribose) polymerase (PARP) inhibitors, designed to specifically target cancer cells with certain genetic mutations.
Chemical Properties	White Solid
Uses	Breast Cancer Treatment: Olaparib is approved for HER2-negative breast cancer patients with specific germline mutations in the BRCA1 or BRCA2 genes. High-Risk Early-Stage Breast Cancer: It's used post-surgery in adults with high-risk early-stage breast cancer that has been treated with chemotherapy before or after surgery.
Definition	ChEBI: A member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)pi erazine; used to treat advanced ovarian cancer.
Onset of Action	The time it takes for olaparib to start working varies depending on the type of cancer being treated. It generally ranges from two to five months, with ovarian cancer treatment potentially taking at least three months to show effectiveness.

InChI:InChI=1/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)

763113-22-0 Relevant articles

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

List of authors. Mark Robson, M.D., Seock-Ah Im, M.D., Ph.D., Elżbieta Senkus, M.D., Ph.D., Binghe Xu, M.D., Ph.D., Susan M. Domchek, M.D., Norikazu Masuda, M.D., Ph.D., Suzette Delaloge, M.D., Wei Li, M.D., Nadine Tung, M.D., Anne Armstrong, M.D., Ph.D., Wenting Wu, Ph.D., Carsten Goessl, M.D

, N Engl J Med 2017; 377:523-533

Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).

PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations

Lisa Hutchinson

, Nature Reviews Clinical Oncology volume 7, page549 (2010)

In the first cohort, patients received 400 mg olaparib twice daily, and in the second cohort they received 100 mg olaparib twice daily. The primary end point was objective response rate (ORR) and safety and tolerability were also assessed.